Zelmac Approved for Chronic Idiopathic Constipation by KFDA

Novartis Korea announced on February 28th that the Korea Food and Drug Administration (KFDA) gave approval for a supplemental indication for its pro-motility drug Zelmac (active ingredient: tegaserod) for the treatment of chronic idiopathic constipation in male and female patients less than 65 years of age.

In the domestic market, Novartis Korea has been marketing Zelmac since September 2003...